Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Dynavax (DVAX) Stock Price & Analysis
2,348 Followers
DVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.06 - $15.15
Previous Close$11.49
Volume2.02M
Average Volume (3M)1.90M
Market Cap
$1.53B
Enterprise Value$1.06B
Total Cash (Recent Filing)$720.42M
Total Debt (Recent Filing)$253.09M
Price to Earnings (P/E)-166.0
Beta1.02
Next Earnings
May 02, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding130,614,772
10 Day Avg. Volume1,496,566
30 Day Avg. Volume1,899,275
Standard Deviation0.24
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.46
Price to Sales (P/S)2.08
Price to Cash Flow (P/CF)27.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.90
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda21.27
Forecast
1Y Price Target
$25.75Price Target Upside124.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dynavax News
PremiumCompany Announcements
Dynavax Appoints Interim CFO During MacDonald’s Leave
PremiumCompany Announcements
Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy
Bulls Say, Bears Say
Bulls Say
Financial OutlookDynavax forecasts a robust financial future with expectations of becoming cash-flow positive, underpinned by solid revenue guidance for Heplisav.
Market PositionHeplisav-B, as the only two-dose adult Hepatitis-B vaccine, coupled with recent guideline changes, is poised to capture growing market opportunities.
Product PerformanceHeplisav-B sales rose significantly, with market share and gross margin continuing to expand, showcasing strong market adoption and financial health.
Bears Say
Market CompetitionQ4 sales were impacted by seasonality and heightened competition from the launch of 2 RSV vaccines, along with COVID re-vaccinations and flu immunizations.
Product DemandRSV/flu/COVID-19 hit 4Q HEPLISAV-B and linger into 1Q24, negatively impacting HEPLISAV-B uptake.
Stock ValuationLimited potential upside for DVAX shares from current levels given the mostly early stage pipeline and scarcity of near-term catalysts.
---
Ownership Overview
25.55% Insiders
25.98% Mutual Funds
36.97% Other Institutional Investors
11.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $10.06 and its highest was $15.15 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Currently, no data Available
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Feb 22, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.011 by $0.011.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is -$0.02.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 130,614,780 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.011. Following the earnings report the stock price went up 2.492%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Among the largest hedge funds holding Dynavax Technologies Corp.’s share is Driehaus Capital Management LLC. It holds Dynavax Technologies Corp.’s shares valued at 22M.
---
Dynavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.75 (124.11% Upside)
$25.75 (124.11% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 156.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.32%
12-Months-Change
Fundamentals
Return on Equity
-1.06%
Trailing 12-Months
Asset Growth
1.14%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DVAX Company Deck
---
DVAX Earnings Call
Q4 2024
0:00 / 0:00
---
DVAX Stock 12 Months Forecast
Average Price Target
$25.75
▲(124.11% Upside)
Technical Analysis
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
13/27 ratings generated profit
1 Year Average Return
+3.00%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +3.00% per trade.
---